Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

North East patients are among the first in the UK to trial Lutetium (177Lu) rhPSMA-10.1, a new targeted treatment for advanced prostate cancer resistant to hormone therapy.

Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Up to 85 percent of prostate cancers are diagnosed in the early stages, when they are still curable.Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.

Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.